Oxford BioTherapeutics partners with Bristol Myers Squibb to develop next-gen T-cell cancer therapies.

Oxford BioTherapeutics (OBT) has entered a multi-year collaboration with Bristol Myers Squibb (BMS) to discover and develop novel T-cell engager therapies for solid tumors using OBT's OGAP®-Verify platform. OBT will lead target discovery and preclinical development, while BMS will handle later-stage research, development, and commercialization. This partnership marks OBT's third major pharma deal in a year, highlighting confidence in their platform's ability to innovate cancer treatments. Financial terms include upfront payments, milestone payments, and royalties, though specifics were not disclosed.